Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited systemic options, and mitotane remains the only systemic therapy specifically indicated for this disease. Resistance is a defining challenge: ACC is biologically heterogeneous, and many tumors progress despite treatment. Understanding how mitotane works, how it is combined with cytotoxic agents, and how exposure is monitored helps explain why it remains central to managing resistant or high-risk ACC.
ACC cells rely on active steroidogenesis and adrenocortical growth signals that mitotane disrupts, but tumor heterogeneity allows subclones to survive initial therapy. Because the disease is rare and often diagnosed at advanced stage, patients frequently present after resistance to first-line approaches has already emerged. This creates a need for combination strategies rather than single-agent reliance, particularly in metastatic or recurrent disease where monotherapy response rates are modest.
In advanced ACC, mitotane is commonly combined with cytotoxic chemotherapy rather than used alone. Streptozocin plus mitotane is a long-established reference combination, and clinical trials have compared mitotane-based doublets (for example streptozocin–mitotane versus etoposide, doxorubicin and cisplatin plus mitotane) in advanced disease. The cytotoxic backbone aims to deliver tumor reduction while mitotane provides disease-specific adrenolytic and steroidogenesis-inhibiting activity, a sequential logic that addresses the multifactorial nature of resistance.
A practical reason resistance appears is variable absorption: mitotane has unpredictable oral bioavailability, and subtherapeutic exposure is associated with disease progression. Clinicians therefore monitor plasma mitotane concentrations and target a recognized therapeutic window (commonly cited around 14–20 mg/L) through gradual dose titration. Sustaining adequate levels is itself a resistance-management tool, because falling below the window permits residual adrenal carcinoma cells to regain steroidogenic and proliferative activity.
Q: Why is mitotane usually combined with chemotherapy in ACC? A: Because single-agent activity is limited in advanced disease, mitotane is paired with a cytotoxic backbone such as streptozocin to improve response while contributing adrenolytic and steroidogenesis-inhibiting effects.
Q: How does plasma monitoring relate to resistance? A: Mitotane absorption is highly variable; monitoring plasma levels and maintaining a therapeutic window helps prevent subtherapeutic exposure that permits tumor progression.
Q: Is mitotane used outside advanced ACC? A: Yes. It is also applied in the adjuvant setting after resection and in managing cortisol excess linked to adrenocortical disease, under specialist supervision.
Q: What formulation is referenced for sourcing? A: The 500 mg tablet strength supplied in a 100-tablet pack is the configuration referenced for this product.
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited systemic options, and mitotane remains the only systemic therapy specifically indicated for this disease. Resistance is a defining challenge: ACC is biologically heterogeneous, and many tumors progress despite treatment. Understanding how mitotane works, how it is combined with cytotoxic agents, and how exposure is monitored helps explain why it remains central to managing resistant or high-risk ACC.
ACC cells rely on active steroidogenesis and adrenocortical growth signals that mitotane disrupts, but tumor heterogeneity allows subclones to survive initial therapy. Because the disease is rare and often diagnosed at advanced stage, patients frequently present after resistance to first-line approaches has already emerged. This creates a need for combination strategies rather than single-agent reliance, particularly in metastatic or recurrent disease where monotherapy response rates are modest.
In advanced ACC, mitotane is commonly combined with cytotoxic chemotherapy rather than used alone. Streptozocin plus mitotane is a long-established reference combination, and clinical trials have compared mitotane-based doublets (for example streptozocin–mitotane versus etoposide, doxorubicin and cisplatin plus mitotane) in advanced disease. The cytotoxic backbone aims to deliver tumor reduction while mitotane provides disease-specific adrenolytic and steroidogenesis-inhibiting activity, a sequential logic that addresses the multifactorial nature of resistance.
A practical reason resistance appears is variable absorption: mitotane has unpredictable oral bioavailability, and subtherapeutic exposure is associated with disease progression. Clinicians therefore monitor plasma mitotane concentrations and target a recognized therapeutic window (commonly cited around 14–20 mg/L) through gradual dose titration. Sustaining adequate levels is itself a resistance-management tool, because falling below the window permits residual adrenal carcinoma cells to regain steroidogenic and proliferative activity.
Q: Why is mitotane usually combined with chemotherapy in ACC? A: Because single-agent activity is limited in advanced disease, mitotane is paired with a cytotoxic backbone such as streptozocin to improve response while contributing adrenolytic and steroidogenesis-inhibiting effects.
Q: How does plasma monitoring relate to resistance? A: Mitotane absorption is highly variable; monitoring plasma levels and maintaining a therapeutic window helps prevent subtherapeutic exposure that permits tumor progression.
Q: Is mitotane used outside advanced ACC? A: Yes. It is also applied in the adjuvant setting after resection and in managing cortisol excess linked to adrenocortical disease, under specialist supervision.
Q: What formulation is referenced for sourcing? A: The 500 mg tablet strength supplied in a 100-tablet pack is the configuration referenced for this product.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
